Sernova

Last week we announced several exciting executive appointments. ✅ James Parsons, Chief Financial Officer, will lead Sernova's finance team and ensure the company’s financial strength to support expanding objectives. ✅ Marylyn Rigby, Chief Communications Officer, will direct Sernova’s comprehensive communication strategies to enhance marketing initiatives, expand media relationships, and elevate investor and stakeholder engagement. ✅ David Burke, Vice President of Investor Relations, will ensure transparent, timely, and effective dialogue with current and prospective investors, building trust and fostering long-term support for Sernova’s visionary projects. Learn more by reading the press release: https://bit.ly/3YnWumv

I'm excited to share our science and clinical data on the Cell Pouch Bio Simulated Organ for Type 1 Diabetes treatment. Join me on Monday October 7th at 10 a.m. to learn more about our journey towards a functional cure. "Giving Patients Their Lives Back!" Details here: https://lnkd.in/gsmd5Jap #celltherapy #type1diabetes #IPSC #isletcells

Please listen to Ginger's interview with Sernova leadership on the merits of our cell based treatment of T1D...progress is being made!

We’re excited to attend the 2024 JDRF/FRDJ Canada Walk to Cure Diabetes in Hamilton, ON, this Sunday, September 22nd, both as a local sponsor, and as members of the global #t1d family, to help raise money for type 1 diabetes research. We can’t wait to meet all the participants, families and introduce ourselves! 😃 The Hamilton JDRF crew has a very exciting day planned in addition to the walk, with all sorts of engaging activities, and fun things to do. If you’re in the area, come out and join us on the walk! If you’d like to donate to our team: Sernova’s Superhero’s, the link is below.👇❤️ DONATE: https://lnkd.in/eqFzpxDV REGISTER FOR THE WALK: https://lnkd.in/edhVqCsk

We are pleased to announce that David Paterson Ph.D. will join Sernova’s Board of Directors effective immediately. Mr. Paterson is currently employed at Colorado State University as Assistant Vice President for Research Translation and Commercialization where he manages strategic industry relationships. In addition, he brings broad biopharma industry knowledge having worked for Impax Laboratories (IPXL: NASDAQ) in both Europe and North America where he provided leadership and Board support to the business development team for ten years until its acquisition by Amneal Pharmaceuticals (AMRX: NASDAQ). Read more from our press release here: https://lnkd.in/eyE2aaVZ

We’re pleased to announce new positive data from our Phase I/II clinical trial evaluating the safety, tolerability, and efficacy of the Sernova Cell Pouch, containing donor islets in people living with type 1 diabetes (T1D). The Lead Investigator for our Phase I//II trial, Piotr Witkowski M.D., Ph.D. stated “This is a major step forward in the development of a contained and retrievable cell therapy for the treatment of T1D. This is the first evidence that I am aware of that demonstrates this level of healthy islet survival and function in an implantable and retrievable system for such a long duration.” Read our full press release here: https://lnkd.in/ezHcv2aP

Today we shared positive interim data from our Phase I/II #ClinicalTrial evaluating our Cell Pouch Transplant System in #Type1Diabetes. Notably, these data show that islets can function and survive within our Cell Pouch for more than 5 years. Learn more about these data and how this milestone further advances our mission of providing a functional cure for #T1D: https://lnkd.in/eZJVjA_z

We are pleased to announce our participation in the upcoming H.C. Wainwright 26th Annual Global Investment Conference in New York. The #HCWainrightGlobal conference showcases the latest innovations, current trends, and emerging technologies globally. Our President & CEO Jonathan Rigby will be presenting on Sept. 11th at 11:00am ET. Read the full press release, and find the online presentation link here: https://lnkd.in/eEjtuZ-9

*New Data to be Presented* Sernova announces today, that Dr. Piotr Witkowski MD PhD, Professor of Surgery, and Director of the Pancreatic and Islet Transplant Program, and his islet transplant team at University of Chicago Medicine, authored an abstract that will be presented, including new data from the ongoing Phase I/II clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D). . This presentation will be held at the European Association for the Study of Diabetes (EASD) on September 12, 2024, in Madrid, Spain. Read our full press release here: https://lnkd.in/g3pRviza

Today we announced the appointment of Jonathan Rigby, Executive Chairman of our Board of Directors, as our Chief Executive Officer. With 30+ years of #biopharma industry experience, he will lead the team as we develop regenerative medicine cell therapies for chronic diseases including #T1D. Learn more by reading our press release: https://bit.ly/4dew24K